Stock Analysts’ updated eps estimates for Monday, August 21st:
Applied Materials (NASDAQ:AMAT) had its buy rating reiterated by analysts at Instinet. The firm currently has a $50.00 target price on the stock, up from their previous target price of $47.00.
Applied Materials (NASDAQ:AMAT) had its neutral rating reiterated by analysts at Susquehanna Bancshares Inc. They currently have a $42.00 target price on the stock.
Amgen (NASDAQ:AMGN) had its buy rating reissued by analysts at Mizuho. They currently have a $183.00 target price on the stock, down from their previous target price of $195.00.
Blue Apron Holdings (NASDAQ:APRN) had its market perform rating reiterated by analysts at Oppenheimer Holdings, Inc..
Blue Apron Holdings (NASDAQ:APRN) had its market perform rating reissued by analysts at CIBC.
Broadcom Limited (NASDAQ:AVGO) had its outperform rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $260.00 price target on the stock.
Broadcom Limited (NASDAQ:AVGO) had its buy rating reaffirmed by analysts at B. Riley. B. Riley currently has a $305.00 price target on the stock. The analysts wrote, “We project moderate upside versus Street estimates led by Wired Infrastructure’s diversified demand and product cycle strength plus Wireless Comms upside from slightly better mid-year iPhone units plus looming 3Q17 Samsung and Apple product cycles with 40% iPhone 8 content gain. Enterprise Storage key customer revenue risks exist but are known and we believe more than offset by strength in 75%+ of the portfolio. Margins should be stellar, with 63.0%/46.0%+ in the outlook. In sum, industry’s diversified networking and communications leader seems well-positioned at mid-year into the seasonally- stronger F2H. We project $5.0B+ in F17 FCF, providing significant value creation flexibility. Wild cards linger such as BRCD $12.28 (NR) deal close timing and cash use until then. In sum we believe RILY F17 and F18 estimates of $15.90 and $17.83, respectively which exclude BRCD have an upside bias and believe positive EPS revision catalysts should persist for the Buy-rated shares trading at just 15.7x and 14.0x our F17/18 EPS with a PT of $305.00.””
Coty (NYSE:COTY) had its sector perform rating reiterated by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $22.00 target price on the stock.
Salesforce.com (NYSE:CRM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $102.00 price target on the stock. According to Zacks, “The leading CRM platform provider, Salesforce has outperformed the industry on a year-to-date basis. We consider the rapid adoption of the Salesforce1 Customer Platform to be a positive. Overall, the company’s diverse cloud offerings and considerable spending on digital marketing remain catalysts. Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run. In view of increasing customer adoption and satisfactory performances, market research firm, Gartner, acknowledged Salesforce as the leading social CRM solution provider. We believe that the rapid adoption of Salesforce’s platforms indicates solid growth opportunities in the ever-growing cloud computing segment. However, currency fluctuations and stepped-up investments in international expansions and data centers could impact near-term results.”
Dynegy (NYSE:DYN) had its buy rating reiterated by analysts at Guggenheim. Guggenheim currently has a $18.00 price target on the stock, up from their previous price target of $14.00.
Estee Lauder Companies, Inc. (The) (NYSE:EL) had its buy rating reaffirmed by analysts at Jefferies Group LLC. Jefferies Group LLC currently has a $112.00 price target on the stock, up from their previous price target of $110.00.
Esperion Therapeutics (NASDAQ:ESPR) had its buy rating reiterated by analysts at Jefferies Group LLC. They currently have a $85.00 target price on the stock.
Graphic Packaging Holding (NYSE:GPK) had its buy rating reissued by analysts at DA Davidson. The firm currently has a $16.50 target price on the stock, down from their previous target price of $17.50.
Howard Bancorp (NASDAQ:HBMD) was upgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a strong-buy rating. The firm currently has $22.00 target price on the stock.
Headlam Group plc (LON:HEAD) had its buy rating reissued by analysts at Investec. Investec currently has a GBX 710 ($9.22) price target on the stock.
Hikma Pharmaceuticals Plc (OTC:HKMPF) was upgraded by analysts at Jefferies Group LLC from an underperform rating to a hold rating.
IDEXX Laboratories (NASDAQ:IDXX) had its buy rating reissued by analysts at Stifel Nicolaus. They currently have a $185.00 target price on the stock.
Kratos Defense & Security Solutions (NASDAQ:KTOS) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $15.00 target price on the stock.
Marvell Technology Group (NASDAQ:MRVL) had its outperform rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $21.00 target price on the stock.
MyoKardia (NASDAQ:MYOK) had its outperform rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $65.00 target price on the stock, up from their previous target price of $45.00.
Nike (NYSE:NKE) had its buy rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). The firm currently has a $58.00 target price on the stock, down from their previous target price of $63.00.
PetMed Express (NASDAQ:PETS) had its hold rating reiterated by analysts at Craig Hallum. They currently have a $40.00 target price on the stock, down from their previous target price of $43.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.
Sandler O’Neill assumed coverage on shares of RBB Bancorp (NYSE:RBB). The firm issued a buy rating on the stock.
Ross Stores (NASDAQ:ROST) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $60.00 price target on the stock. According to Zacks, “Ross Stores has outperformed the broader industry in the past year, given its positive record of earnings surprises in 12 of the trailing 13 quarters. In second-quarter fiscal 2017, both the top and bottom lines topped estimates and improved year over year. Results gained from solid top-line growth that was driven by broad-based growth across all merchandise categories and regions. Further, better-than-expected sales and operating profits at dd's DISCOUNTS aided results. Concluding first-half fiscal 2017 on a strong note, the company provided guidance for the second half and accordingly raised earnings view for fiscal 2017. This led to an uptrend in estimates for fiscal 2017. Moreover, its solid financial status, ongoing merchandise initiatives and consistent focus on-store expansion bode well. However, the company anticipates witnessing the most challenging year-ago comparisons in second-half fiscal 2017, alongside a volatile retail backdrop.”
RSA Insurance Group plc (OTC:RSNAY) was upgraded by analysts at Royal Bank Of Canada from a sector perform rating to an outperform rating.
Argus started coverage on shares of Schlumberger N.V. (NYSE:SLB). They issued a buy rating on the stock.
Synopsys (NASDAQ:SNPS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $86.00 target price on the stock. According to Zacks, “Synopsys is a vendor of electronic design automation (EDA) software to the semiconductor and electronics industries. The company posted impressive fiscal third-quarter results. Revenues as well as earnings improved year over year, mainly due to strength in hardware and IP products. Additionally, the company’s fourth-quarter and upbeat fiscal 2017 guidance are encouraging. We believe that the company’s sustained focus on introducing new products, acquisitions and deal wins will continue to boost results, going ahead. Moreover, unique intellectual properties and global support provided by the company will likely drive its forthcoming results. Additionally, the acquisition of Cigital and Codiscope will enable Synopsys to offer a comprehensive software security signoff solution to its customers. Notably, shares of Synopsys has outperformed the industry over the past one year.”
Syros Pharmaceuticals (NASDAQ:SYRS) had its buy rating reissued by analysts at Cann. Cann currently has a $28.00 target price on the stock. The analysts wrote, “Syros announced today that FDA has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.””
Triumph Bancorp (NASDAQ:TBK) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $34.00 price target on the stock.
Toronto Dominion Bank (The) (NYSE:TD) (TSE:TD) was upgraded by analysts at Howard Weil to an outperform rating.
Toronto Dominion Bank (The) (NYSE:TD) (TSE:TD) was upgraded by analysts at Scotiabank from a sector perform rating to an outperform rating.
TherapeuticsMD (NASDAQ:TXMD) had its buy rating reiterated by analysts at Stifel Nicolaus. They currently have a $20.00 price target on the stock.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) had its buy rating reiterated by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $45.00 target price on the stock.
Western Digital Corporation (NASDAQ:WDC) had its buy rating reiterated by analysts at Citigroup Inc.. The firm currently has a $110.00 target price on the stock, down from their previous target price of $115.00.
Williams-Sonoma (NYSE:WSM) had its sell rating reissued by analysts at BTIG Research. They currently have a $41.00 target price on the stock.
